Temperature-controlled supply chain firm Cryoport has sold its CRYOPDP business, a courier focused on clinical trials, biopharma, and cell and gene therapies, to German logistics multinational DHL Group.
In addition to the business sale, Cryoport has also confirmed a partnership with DHL to strengthen their respective offerings.
For DHL, the deal will enhance its capabilities in pharma logistics and expand its offering in the life sciences sector.
Oscar de Bok, CEO of DHL Supply Chain, described the purchase as a “pivotal move” for the company’, as it would allow the company to offer more to its pharma-specialised network.
CRYOPDP handles over 600,000 shipments per year, servicing customers and patients in over 135 countries worldwide.
A lot of gene therapies need to be stabilised by cryogenic preservation for storage and transportation. Speaking to gasworld previously, Cryoport’s CEO described cryogenics as the medium that maintains the temperature profile of the cellular materials.
Jerrell Shelton, CEO of Cryoport, said the deal and especially the partnership element also presents his company with an opportunity to grow into certain country markets where its reach has so far been limited,
